Wegovy’s new pricing could save you $1,200—but it’s not for everyone

Multi-month subscriptions promise big savings for those willing to commit.

[Photo: Shelby Knowles/Bloomberg via Getty Images]

Novo Nordisk just launched a new subscription program for Wegovy customers. 

In an announcement Tuesday, the Danish GLP-1 maker said the new program will help “reduce cost uncertainty” so that people can maintain access to their obesity drugs. Wegovy contains semaglutide, a glucagon-like peptide-1 receptor agonist used for chronic weight management. Novo Nordisk also promised savings of up to $600 per year for the pill form of the drug and up to $1,200 per year for the injections with a 12-month subscription. 

Eligible patients........

© Fast Company